Please provide your email address to receive an email when new articles are posted on . Zhang and colleagues obtained data from the Surveillance, Epidemiology, and End Results program from 69,562 ...

July 30, 2009 — Clinicians who diagnose oropharyngeal cancer should now test their patients' tumor tissue for human papillomavirus (HPV), say experts. HPV-positive cancers of the head and neck have ...

The HPV vaccine is an impressive health multitasker. The vaccine, which targets the human papillomavirus, can help protect your kids from developing six types of cancer in adulthood. It's also highly ...

In 2015, oropharyngeal squamous cell carcinoma surpassed cervical cancer as the most common HPV-associated cancer in the U.S., with 15,479 cases among men and 3,438 cases among women, according to ...

March 30, 2010 — The incidence of oropharyngeal carcinoma related to human papillomavirus (HPV) has been increasing in recent years, and there is speculation that this is the result of the "sexual ...

Although the human papillomavirus (HPV) is a risk factor for certain head and neck cancers, its presence could make all the difference in terms of survival, especially for African Americans with ...

Oropharyngeal (OP) cancers associated with the human papillomavirus (HPV) are increasing, especially among younger patients, but these patients have a better prognosis than those with HPV-negative ...

DelveInsight's HPV+ Oropharyngeal Cancer Market Insights report includes a comprehensive understanding of current treatment practices, HPV+ oropharyngeal cancer emerging drugs, market share of ...

Alexandria, VA, USA – Shillpa Naavaal, Virginia Commonwealth University, Richmond, presented “From Cervical Cancers to Oropharyngeal: HPV Research in Rural Communities” at the hybrid 51 st Annual ...

The prevalence of throat (oropharyngeal) cancers caused by the human papilloma virus (HPV) has increased in recent decades, and some groups are much more likely than others to have the oral HPV ...

The HPV+ oropharyngeal cancer market is expanding rapidly, driven by a rising incidence of HPV-driven OPSCC and growing clinician awareness. The anticipated launch of emerging therapies such as Merck ...